{"disease":{"id":"multiple-myeloma","name":"Multiple Myeloma","therapeutic_area":"Oncology / Haematology","data":{"aiSummary":"Multiple myeloma treatment has undergone a revolution with the anti-CD38 antibody daratumumab now embedded in first-line quadruplet regimens (Dara-VRd, PERSEUS) achieving unprecedented MRD negativity rates >75% and markedly prolonged PFS. The relapsed/refractory setting has been transformed by two converging innovations: BCMA-targeted CAR-T cell therapies, with ciltacabtagene autoleucel (Carvykti) delivering ORRs approaching 98% and now moving into earlier lines (CARTITUDE-4), and bispecific T-cell redirecting antibodies (teclistamab, elranatamab, talquetamab) providing off-the-shelf options for triple-class refractory disease. The major outstanding challenge is defining optimal sequencing of these agents and overcoming the increasing problem of post-CAR-T and post-bispecific resistance, where next-generation CELMoDs (mezigdomide) and novel combinations are being evaluated.","drug_count":12,"description":"Multiple myeloma (MM) is a haematological malignancy of clonal plasma cells that accumulate in the bone marrow, producing monoclonal immunoglobulin (M-protein or paraprotein) and causing end-organ damage (CRAB criteria: hyperCalcaemia, Renal impairment, Anaemia, Bone lesions). It is the second most common haematological cancer after non-Hodgkin lymphoma. While considered incurable, median overall survival has improved dramatically over the past two decades — from ~3 years in the early 2000s to now exceeding 10 years in transplant-eligible patients — driven by successive waves of therapeutic innovation: immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), anti-CD38 monoclonal antibodies (daratumumab, isatuximab), and most recently, T-cell redirecting bispecific antibodies and BCMA-targeted CAR-T cell therapies.","subtype_count":11},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.945Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":55,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"daratumumab","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex","generic_name":"daratumumab","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"CD38","drug_class":"Monoclonal antibody","quality_score":78,"revenue":"11800","mechanism":"Daratumumab binds CD38 on tumor cells, inducing apoptosis and immune-mediated lysis via CDC, ADCC, and ADCP."},{"drug_id":"lenalidomide","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revlimid","generic_name":"lenalidomide","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cereblon (component of cullin ring E3 ubiquitin ligase enzyme complex)","drug_class":"Thalidomide analogue","quality_score":88,"revenue":"5809","mechanism":"Lenalidomide targets cereblon to degrade substrate proteins, inducing cytotoxicity and immunomodulation."},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pf-06863135-lenalidomide","indication_name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + lenalidomide","generic_name":"pf-06863135-lenalidomide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"small molecule + immunomodulatory drug","quality_score":45,"revenue":"2951","mechanism":""},{"drug_id":"pomalidomide","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pomalyst","generic_name":"pomalidomide","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Protein cereblon","drug_class":"Thalidomide Analog [EPC]","quality_score":84,"revenue":"2800","mechanism":"Pomalyst works by binding to the cereblon protein, which disrupts the function of certain genes involved in cancer cell growth."},{"drug_id":"carfilzomib","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kyprolis","generic_name":"carfilzomib","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Proteasome subunit beta type-5","drug_class":"Proteasome Inhibitor [EPC]","quality_score":82,"revenue":"1300","mechanism":"Kyprolis works by blocking the proteasome, a complex that breaks down proteins in cells."},{"drug_id":"carfilzomib","indication_name":"Relapse multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kyprolis","generic_name":"carfilzomib","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Proteasome subunit beta type-5","drug_class":"Proteasome Inhibitor [EPC]","quality_score":82,"revenue":"1300","mechanism":"Kyprolis works by blocking the proteasome, a complex that breaks down proteins in cells."},{"drug_id":"ciltacabtagene-autoleucel","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carvykti","generic_name":"ciltacabtagene autoleucel","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":"1100","mechanism":null},{"drug_id":"ciltacabtagene-autoleucel","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carvykti","generic_name":"ciltacabtagene autoleucel","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":"1100","mechanism":null},{"drug_id":"cyclophosphamide","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":88,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"hyaluronidase","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wydase","generic_name":"HYALURONIDASE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"hyaluronic acid","drug_class":"Endoglycosidase","quality_score":69,"revenue":"900","mechanism":"Hyaluronidase increases tissue permeability by breaking down hyaluronic acid, promoting the diffusion and absorption of injected fluids."},{"drug_id":"ixazomib","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ninlaro","generic_name":"IXAZOMIB","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Proteasome subunit beta type-5","drug_class":"Proteasome Inhibitor","quality_score":65,"revenue":"600","mechanism":"Ninlaro blocks the action of proteasomes, which are cellular complexes that break down and recycle proteins."},{"drug_id":"ninlaro","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ninlaro","generic_name":"Ninlaro","company_name":"Millennium Pharms","drug_phase":"discontinued","molecular_target":"Proteasome subunit beta type-5","drug_class":"Proteasome Inhibitor","quality_score":null,"revenue":"600","mechanism":"Ninlaro works by blocking the proteasome, a cellular complex that breaks down proteins, leading to cell death in cancer cells."},{"drug_id":"isatuximab","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hu38Sb19","generic_name":"isatuximab","company_name":"Sanofi","drug_phase":"discontinued","molecular_target":"Lymphocyte differentiation antigen CD38","drug_class":"CD38-directed Cytolytic Antibody","quality_score":null,"revenue":"500","mechanism":"Isatuximab works by binding to the CD38 protein on cancer cells, triggering a response that leads to their destruction."},{"drug_id":"teclistamab","indication_name":"Relapsed or Refractory Multiple Myeloma (Monotherapy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bcmaxcd3","generic_name":"TECLISTAMAB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"CD3, BCMA","drug_class":"","quality_score":67,"revenue":"400","mechanism":"Teclistamab-cqyv activates T-cells by binding to CD3 and BCMA, leading to the lysis of multiple myeloma cells."},{"drug_id":"teclistamab","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bcmaxcd3","generic_name":"TECLISTAMAB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"CD3, BCMA","drug_class":"","quality_score":67,"revenue":"400","mechanism":"Teclistamab-cqyv activates T-cells by binding to CD3 and BCMA, leading to the lysis of multiple myeloma cells."},{"drug_id":"teclistamab","indication_name":"Relapsed or Refractory Multiple Myeloma (Combination Therapy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bcmaxcd3","generic_name":"TECLISTAMAB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"CD3, BCMA","drug_class":"","quality_score":67,"revenue":"400","mechanism":"Teclistamab-cqyv activates T-cells by binding to CD3 and BCMA, leading to the lysis of multiple myeloma cells."},{"drug_id":"talquetamab","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talvey","generic_name":"TALQUETAMAB","company_name":"Janssen Biotech ","drug_phase":"marketed","molecular_target":"T-cell surface glycoprotein CD3","drug_class":"","quality_score":63,"revenue":"400","mechanism":"Talquetamab binds to the T-cell surface glycoprotein CD3, triggering a response that kills cancer cells."},{"drug_id":"elrexfio","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elrexfio","generic_name":"Elranatamab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells","drug_class":"Bispecific antibody","quality_score":81,"revenue":"304","mechanism":"Bispecific antibody binding BCMA on myeloma cells and CD3 on T-cells, causing cytolysis."},{"drug_id":"elranatamab-bcmm","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elrexfio","generic_name":"elranatamab-bcmm","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tumor necrosis factor receptor superfamily member 17","drug_class":"","quality_score":68,"revenue":"304","mechanism":"Elrexfio works by binding to tumor necrosis factor receptor superfamily member 17, a protein involved in the growth and survival of cancer cells."},{"drug_id":"elranatamab","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elrexfio","generic_name":"elranatamab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells","drug_class":"Bispecific antibody","quality_score":74,"revenue":"304","mechanism":"Bispecific antibody binding BCMA on myeloma cells and CD3 on T-cells, causing cytolysis."},{"drug_id":"belantamab-mafodotin","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Blenrep","generic_name":"BELANTAMAB MAFODOTIN","company_name":"GSK","drug_phase":"marketed","molecular_target":"BCMA","drug_class":"","quality_score":63,"revenue":"300","mechanism":"Belantamab mafodotin binds to BCMA on multiple myeloma cells, is internalized, and releases a cytotoxic agent that disrupts microtubules, causing cell death."},{"drug_id":"belantamab-mafodotin","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Blenrep","generic_name":"BELANTAMAB MAFODOTIN","company_name":"GSK","drug_phase":"marketed","molecular_target":"BCMA","drug_class":"","quality_score":63,"revenue":"300","mechanism":"Belantamab mafodotin binds to BCMA on multiple myeloma cells, is internalized, and releases a cytotoxic agent that disrupts microtubules, causing cell death."},{"drug_id":"belantamab-mafodotin","indication_name":"Relapse multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Blenrep","generic_name":"BELANTAMAB MAFODOTIN","company_name":"GSK","drug_phase":"marketed","molecular_target":"BCMA","drug_class":"","quality_score":63,"revenue":"300","mechanism":"Belantamab mafodotin binds to BCMA on multiple myeloma cells, is internalized, and releases a cytotoxic agent that disrupts microtubules, causing cell death."},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 8 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 9 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 9 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 9 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 9 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 10 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 10 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 10 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 10 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 11 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 11 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 11 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 11 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 12 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 12 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 12 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 12 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 13 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 13 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 13 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 13 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 14 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 14 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 14 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 14 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 15 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 15 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 15 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 15 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 16 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 16 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 16 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 16 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 17 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 17 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 17 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 17 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 18 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 18 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 18 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 18 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 19 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 27 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 4 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 5 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 6 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 7 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 8 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 9 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 10 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 28 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 29 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 30 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 31 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 32 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 33 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 2 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 3 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 11 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 12 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 13 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 14 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 15 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 16 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 17 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 18 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 19 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 20 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 21 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 22 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 23 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 24 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 25 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 26 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 34 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 35 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 36 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 37 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 38 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 39 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 40 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 41 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 42 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 43 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 44 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 45 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 46 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 47 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 48 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 49 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 50 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 51 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 52 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 53 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 54 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 55 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 56 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 57 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 58 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 59 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 60 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 61 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 62 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 63 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 64 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 65 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 66 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 67 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 68 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 69 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 70 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 71 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 72 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 73 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 74 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 75 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 76 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 77 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 78 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 79 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 80 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 81 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 82 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 83 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 84 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 85 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 86 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 87 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 88 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 89 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 90 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 91 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 92 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 93 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 94 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 95 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"pf-04171327","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 96 prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-04171327","generic_name":"pf-04171327","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Selective glucocorticoid receptor modulator (SGRM)","quality_score":52,"revenue":null,"mechanism":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM)."},{"drug_id":"motixafortide","indication_name":"multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aphexda","generic_name":"MOTIXAFORTIDE","company_name":"Ayrmid Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Aphexda works by binding to its target, which is currently unknown, to exert its therapeutic effects."},{"drug_id":"panobinostat","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Farydak","generic_name":"PANOBINOSTAT","company_name":"Secura","drug_phase":"marketed","molecular_target":"Histone deacetylase 4","drug_class":"Histone Deacetylase Inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-acetate","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron-La","generic_name":"DEXAMETHASONE ACETATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"carmustine","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gliadel","generic_name":"CARMUSTINE","company_name":"Avet Lifesciences","drug_phase":"marketed","molecular_target":"Glutathione reductase, mitochondrial","drug_class":"Alkylating Drug","quality_score":69,"revenue":null,"mechanism":"Gliadel works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow."},{"drug_id":"plerixafor","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mozobil","generic_name":"plerixafor","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"C-C chemokine receptor type 2","drug_class":"Hematopoietic Stem Cell Mobilizer [EPC]","quality_score":61,"revenue":null,"mechanism":"Mozobil works by binding to the C-C chemokine receptor type 2, which helps to mobilize hematopoietic stem cells from the bone marrow into the bloodstream."},{"drug_id":"pf-07985631","indication_name":"Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"linvoseltamab","indication_name":"relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lynozyfic","generic_name":"LINVOSELTAMAB","company_name":"Rengeneron Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"Bispecific B Cell Maturation Antigen-directed CD3 T Cell Engager [EPC]","quality_score":52,"revenue":null,"mechanism":"Lynozyfic works by binding to specific cells involved in multiple myeloma."},{"drug_id":"linvoseltamab","indication_name":"relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lynozyfic","generic_name":"LINVOSELTAMAB","company_name":"Rengeneron Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"Bispecific B Cell Maturation Antigen-directed CD3 T Cell Engager [EPC]","quality_score":52,"revenue":null,"mechanism":"Lynozyfic works by binding to specific cells involved in multiple myeloma."},{"drug_id":"farydak","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Farydak","company_name":"Novartis Pharmaceuticals","drug_phase":"discontinued","molecular_target":"Bromodomain-containing protein 4, Histone deacetylase 1, Histone deacetylase 10","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"elrantamab","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elrantamab","generic_name":"elrantamab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCMA (B-cell maturation antigen)","drug_class":"Bispecific Antibody","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060","indication_name":"Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07220060","generic_name":"pf-07220060","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in disease pathways","drug_class":"Small molecule inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"pf-07248144","indication_name":"Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07248144","generic_name":"pf-07248144","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in disease pathways","drug_class":"Small molecule inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"pf-07248144","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07248144","generic_name":"pf-07248144","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in disease pathways","drug_class":"Small molecule inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"melflufen","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Melflufen","company_name":"Oncopeptides AB","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"alkeran","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"alkeran","company_name":"French Innovative Leukemia Organisation","drug_phase":"phase_2","molecular_target":"L-type amino acid transporter 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pf-07264660","indication_name":"Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07264660","generic_name":"pf-07264660","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":34,"revenue":null,"mechanism":"The mechanism of action of PF-07264660 is not specified."},{"drug_id":"pf-07264660","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07264660","generic_name":"pf-07264660","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":34,"revenue":null,"mechanism":"The mechanism of action of PF-07264660 is not specified."},{"drug_id":"pf-07293893","indication_name":"Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07293893","generic_name":"pf-07293893","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) pathway","drug_class":"JAK inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"pf-07293893","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07293893","generic_name":"pf-07293893","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) pathway","drug_class":"JAK inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"adriacin","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"kyprolis","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Kyprolis","company_name":"Black Sea Hematology Association","drug_phase":"marketed","molecular_target":"Cathepsin B, Glutathione S-transferase omega-1, Proteasome subunit beta type-10","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"kyprolis","indication_name":"Relapse multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Kyprolis","company_name":"Black Sea Hematology Association","drug_phase":"marketed","molecular_target":"Cathepsin B, Glutathione S-transferase omega-1, Proteasome subunit beta type-10","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pamidronate","indication_name":"Osteolytic Lesions of Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pamidronate","company_name":"US Department of Veterans Affairs","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Hypoxanthine-guanine phosphoribosyltransferase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"thalomid","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Thalomid","company_name":"Ann & Robert H Lurie Children's Hospital of Chicago","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Protein cereblon","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"cyclophosphamid","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"blenrep","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Blenrep","company_name":"Duke University","drug_phase":"marketed","molecular_target":"Low affinity immunoglobulin gamma Fc region receptor III-A, High affinity immunoglobulin gamma Fc receptor I, IgG receptor FcRn large subunit p51","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"blenrep","indication_name":"Relapse multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Blenrep","company_name":"Duke University","drug_phase":"marketed","molecular_target":"Low affinity immunoglobulin gamma Fc region receptor III-A, High affinity immunoglobulin gamma Fc receptor I, IgG receptor FcRn large subunit p51","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"velcade","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Velcade","company_name":"University of Arkansas","drug_phase":"marketed","molecular_target":"26S proteasome non-ATPase regulatory subunit 1, PH and SEC7 domain-containing protein 1, Cathepsin G","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"pf-08032562","indication_name":"Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08032562","generic_name":"pf-08032562","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"unknown","drug_class":"unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07940369","indication_name":"Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07940369","generic_name":"pf-07940369","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Not available","drug_class":"Not available","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"isatuximab-irfc","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SARCLISA","generic_name":"ISATUXIMAB-IRFC","company_name":"SANOFI AVENTIS US","drug_phase":"marketed","molecular_target":"Lymphocyte differentiation antigen CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"teclistamab-cqyv","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TECVAYLI","generic_name":"TECLISTAMAB-CQYV","company_name":"JANSSEN BIOTECH","drug_phase":"marketed","molecular_target":"Tumor necrosis factor receptor superfamily member 17, T-cell surface glycoprotein CD3","drug_class":"","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"talquetamab-tgvs","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TALVEY","generic_name":"TALQUETAMAB-TGVS","company_name":"JANSSEN BIOTECH","drug_phase":"marketed","molecular_target":"G-protein coupled receptor family C group 5 member D, T-cell surface glycoprotein CD3","drug_class":"","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"pf-07284892","indication_name":"Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284892","generic_name":"pf-07284892","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"unknown","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"pf-07284892","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284892","generic_name":"pf-07284892","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"unknown","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"oral-pf-07220060","indication_name":"Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oral PF-07220060","generic_name":"oral-pf-07220060","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"oral-pf-07220060","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oral PF-07220060","generic_name":"oral-pf-07220060","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"pamidronic-acid","indication_name":"Osteolytic Lesions of Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aredia","generic_name":"PAMIDRONIC ACID","company_name":"","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"Bisphosphonate","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"thalidomide","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thalomid","generic_name":"THALIDOMIDE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"thalidomide","quality_score":67,"revenue":null,"mechanism":"Thalomid works by inhibiting the production of tumor necrosis factor, a protein that promotes inflammation and tumor growth."},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"bortezomib","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velcade","generic_name":"bortezomib","company_name":"Shilpa","drug_phase":"marketed","molecular_target":"26S proteasome chymotrypsin-like activity","drug_class":"Proteasome inhibitor","quality_score":76,"revenue":null,"mechanism":"Reversible inhibitor of 26S proteasome chymotrypsin-like activity preventing ubiquitinated protein degradation."},{"drug_id":"pf-07923568","indication_name":"Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07923568","generic_name":"pf-07923568","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown target","drug_class":"Unknown pharmacological class","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"carmustin","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carmustin","company_name":"University Hospital Freiburg","drug_phase":"marketed","molecular_target":"Glutathione reductase, mitochondrial","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"mozobil","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mozobil","company_name":"University of Washington","drug_phase":"marketed","molecular_target":"Stromal cell-derived factor 1, Atypical chemokine receptor 3, C-C chemokine receptor type 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"pf-08049820-mr2","indication_name":"Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 2 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 3 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 4 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 5 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 6 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 7 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 8 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 9 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 10 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 11 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 12 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 13 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 14 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 15 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 16 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 17 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 18 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 19 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 20 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 21 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 22 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 23 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 24 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 25 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 26 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 27 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 28 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 29 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 30 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 31 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 32 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 33 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 34 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 35 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 36 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 37 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 38 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 39 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 40 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 41 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 42 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 43 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 44 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 45 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 46 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 47 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 48 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 49 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 50 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 51 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 52 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 53 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 54 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 55 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 56 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 57 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 58 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 59 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 60 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 61 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 62 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 63 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 64 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 65 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 66 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 67 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 68 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 69 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 70 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 71 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 72 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 73 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 74 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 75 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 76 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 77 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 78 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 79 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 80 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 81 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 82 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 83 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 84 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 85 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 86 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 87 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 88 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 89 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 90 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 91 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 92 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 93 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 94 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 95 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 96 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 97 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 98 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 99 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 100 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 101 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 102 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08049820-mr2","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 103 prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08049820 Mr2","generic_name":"pf-08049820-mr2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"High-Risk Smoldering Multiple Myeloma as monotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"melphalan-flufenamide","indication_name":"Relapsed or refractory multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pepaxto","generic_name":"MELPHALAN FLUFENAMIDE","company_name":"Oncopeptides Ab","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"elotuzumab","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Huluc63","generic_name":"elotuzumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"SLAM family member 7","drug_class":"SLAMF7-directed Immunostimulatory Antibody [EPC]","quality_score":70,"revenue":null,"mechanism":"Huluc63 works by binding to the SLAMF7 protein on the surface of cancer cells, stimulating the immune system to attack and kill the cells."},{"drug_id":"elotuzumab","indication_name":"Relapse multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Huluc63","generic_name":"elotuzumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"SLAM family member 7","drug_class":"SLAMF7-directed Immunostimulatory Antibody [EPC]","quality_score":70,"revenue":null,"mechanism":"Huluc63 works by binding to the SLAMF7 protein on the surface of cancer cells, stimulating the immune system to attack and kill the cells."},{"drug_id":"liposomal-doxorubicin","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-06863135-dexamethasone","indication_name":"Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06863135 + dexamethasone","generic_name":"pf-06863135-dexamethasone","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"poma","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"POMA","company_name":"Bristol","drug_phase":"marketed","molecular_target":"Protein cereblon, Cereblon isoform 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Poma is a small molecule that works by interacting with a specific biological target to produce a therapeutic effect."},{"drug_id":"zoledronic-acid","indication_name":"Osteolytic Lesions of Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zometa","generic_name":"ZOLEDRONIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"zoledronic acid","quality_score":80,"revenue":null,"mechanism":"Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity."},{"drug_id":"melphalan","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alkeran","generic_name":"melphalan","company_name":"Apotex","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"doxorubicin","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"chembl-chembl1200796","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":80,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"darzalex","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Darzalex","company_name":"Shanghai Henlius Biotech","drug_phase":"marketed","molecular_target":"Lymphocyte differentiation antigen CD38","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunomycin","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lenali","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lenali","company_name":"Singapore General Hospital","drug_phase":"marketed","molecular_target":"Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zometa","indication_name":"Osteolytic Lesions of Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zometa","company_name":"University of Arkansas","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"revlimid","indication_name":"Multiple myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Revlimid","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma - Induction/Consolidation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"zoledronate","indication_name":"Osteolytic Lesions of Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zoledronate","company_name":"Children's Hospital Medical Center, Cincinnati","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma - Ineligible for Transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma - Melphalan/Prednisone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma - Lenalidomide/Dexamethasone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma - Thalidomide","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma - Bortezomib/Dexamethasone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma - Pomalidomide/Dexamethasone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma - Carfilzomib/Dexamethasone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma - Monotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"High-Risk Smoldering Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"teclistamab-cqyv","indication_name":"Relapsed or Refractory Multiple Myeloma (Combination Therapy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TECVAYLI","generic_name":"TECLISTAMAB-CQYV","company_name":"JANSSEN BIOTECH","drug_phase":"marketed","molecular_target":"Tumor necrosis factor receptor superfamily member 17, T-cell surface glycoprotein CD3","drug_class":"","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"teclistamab-cqyv","indication_name":"Relapsed or Refractory Multiple Myeloma (Monotherapy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TECVAYLI","generic_name":"TECLISTAMAB-CQYV","company_name":"JANSSEN BIOTECH","drug_phase":"marketed","molecular_target":"Tumor necrosis factor receptor superfamily member 17, T-cell surface glycoprotein CD3","drug_class":"","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"thalidomide","indication_name":"Newly Diagnosed Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thalomid","generic_name":"THALIDOMIDE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"thalidomide","quality_score":67,"revenue":null,"mechanism":"Thalomid works by inhibiting the production of tumor necrosis factor, a protein that promotes inflammation and tumor growth."},{"drug_id":"zoledronic-acid","indication_name":"Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zometa","generic_name":"ZOLEDRONIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"zoledronic acid","quality_score":80,"revenue":null,"mechanism":"Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity."},{"drug_id":"chembl-chembl3545131","indication_name":"Multiple Myeloma (≥2 prior therapies)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ISATUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3545131","indication_name":"Relapsed or Refractory Multiple Myeloma (1-3 prior therapies)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ISATUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3545131","indication_name":"Newly Diagnosed Multiple Myeloma (Not Eligible for ASCT)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ISATUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"pf-07284890","indication_name":"Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 5 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 5 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 5 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 5 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 6 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 6 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 6 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 6 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 7 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 7 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 7 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 7 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 8 lines of therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 8 lines of therapy and a proteasome inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 8 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":418,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05775224","title":"ASH Research Collaborative Data Hub","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100000,"lead_sponsor_name":"ASH Research Collaborative","has_results":false},{"nct_id":"NCT00352924","title":"Agriculture Health Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":89655,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03689595","title":"Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT06750965","title":"Multi-center Screening for Serum M Protein","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT06082284","title":"A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method.","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05556928","title":"Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT00900198","title":"Collection of Tissue Samples for Cancer Research","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02921802","title":"A Study of Special Use Results Surveillance of Revlimid 5mg Capsules","phase":"","overall_status":"COMPLETED","enrollment_count":4626,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT02761187","title":"An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants","phase":"","overall_status":"TERMINATED","enrollment_count":4253,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT06160167","title":"Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs","phase":"","overall_status":"COMPLETED","enrollment_count":4204,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT02693535","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":4200,"lead_sponsor_name":"American Society of Clinical Oncology","has_results":false},{"nct_id":"NCT04314752","title":"Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"University of California, Davis","has_results":false},{"nct_id":"NCT01081028","title":"Connect® MM- The Multiple Myeloma Disease Registry","phase":"","overall_status":"TERMINATED","enrollment_count":3011,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT00626496","title":"Family Study of Lymphoproliferative Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06690593","title":"Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy","phase":"","overall_status":"RECRUITING","enrollment_count":2990,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT01838512","title":"Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2555,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT02902900","title":"An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":2504,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT04955808","title":"Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery","phase":"","overall_status":"SUSPENDED","enrollment_count":2400,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04645199","title":"National Longitudinal Cohort of Hematological Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06409767","title":"Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.","phase":"NA","overall_status":"RECRUITING","enrollment_count":2224,"lead_sponsor_name":"University Hospital, Angers","has_results":false},{"nct_id":"NCT05655546","title":"ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals","phase":"NA","overall_status":"TERMINATED","enrollment_count":2117,"lead_sponsor_name":"Scripps Translational Science Institute","has_results":true},{"nct_id":"NCT03955900","title":"A Registry Study of Participants With Multiple Myeloma in Latin America","phase":"","overall_status":"COMPLETED","enrollment_count":2059,"lead_sponsor_name":"Janssen-Cilag Ltd.","has_results":false},{"nct_id":"NCT06760052","title":"Longitudinal Data Registry of Plasma Cell Dyscrasia","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT05283993","title":"A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT05001087","title":"A \"Physician & Patient-powered\" Cohort Registry (MY MYELOMA)","phase":"","overall_status":"RECRUITING","enrollment_count":1900,"lead_sponsor_name":"Fondazione EMN Italy Onlus","has_results":false},{"nct_id":"NCT01139476","title":"Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study","phase":"","overall_status":"COMPLETED","enrollment_count":1892,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01345019","title":"Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1718,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT00689936","title":"Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1623,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05552222","title":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1590,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT07428369","title":"A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1570,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT06825845","title":"Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"CARsgen Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT03807128","title":"MYeloma Resistance And Clonal Evolution","phase":"","overall_status":"RECRUITING","enrollment_count":1400,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT00339963","title":"Genome Expression in Lymphoma, Leukemia and Multiple Myeloma","phase":"","overall_status":"COMPLETED","enrollment_count":1340,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01676805","title":"Tissue Collection for Studies of Lymph Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1295,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05827016","title":"A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1216,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT02921828","title":"A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg","phase":"","overall_status":"COMPLETED","enrollment_count":1149,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT05623020","title":"A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1116,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03657251","title":"MMRF CureCloud Research Initiative","phase":"","overall_status":"TERMINATED","enrollment_count":1105,"lead_sponsor_name":"Multiple Myeloma Research Foundation","has_results":false},{"nct_id":"NCT04071457","title":"S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1100,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT04492371","title":"COVID-19 Infection and Multiple Myeloma","phase":"","overall_status":"COMPLETED","enrollment_count":1054,"lead_sponsor_name":"Stichting European Myeloma Network","has_results":false},{"nct_id":"NCT07205523","title":"High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Yigeng Cao,MD,PhD","has_results":false},{"nct_id":"NCT05331313","title":"The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT05361694","title":"Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT06366802","title":"Cohort Construction and Prognostic Model Construction for Multiple Myeloma","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT02473757","title":"Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06340646","title":"Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)","phase":"NA","overall_status":"RECRUITING","enrollment_count":990,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT05556720","title":"Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":960,"lead_sponsor_name":"Monash University","has_results":false},{"nct_id":"NCT01818752","title":"Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":955,"lead_sponsor_name":"Amgen","has_results":true}],"total":50},"guidelines":[{"drug_id":"daratumumab","guideline_body":"FDA label","recommendation":"DARZALEX FASPRO in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"daratumumab","guideline_body":"FDA label","recommendation":"DARZALEX FASPRO in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"daratumumab","guideline_body":"FDA label","recommendation":"DARZALEX FASPRO in combination with bortezomib, melphalan, and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"daratumumab","guideline_body":"FDA label","recommendation":"DARZALEX FASPRO in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"daratumumab","guideline_body":"FDA label","recommendation":"DARZALEX FASPRO in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"daratumumab","guideline_body":"FDA label","recommendation":"DARZALEX FASPRO in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"daratumumab","guideline_body":"FDA label","recommendation":"DARZALEX FASPRO in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"daratumumab","guideline_body":"FDA label","recommendation":"DARZALEX FASPRO in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"daratumumab","guideline_body":"FDA label","recommendation":"DARZALEX FASPRO in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"daratumumab","guideline_body":"FDA label","recommendation":"DARZALEX FASPRO as monotherapy in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.","line_of_therapy":"3L+","evidence_grade":"not specified","guideline_year":null},{"drug_id":"bortezomib","guideline_body":"FDA label","recommendation":"Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"bortezomib","guideline_body":"FDA label","recommendation":"Bortezomib for injection is indicated for the treatment of adult patients with mantle cell lymphoma.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"bortezomib","guideline_body":"FDA label","recommendation":"Bortezomib for injection is indicated for the treatment of adult patients with systemic AL amyloidosis.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"elotuzumab","guideline_body":"FDA label","recommendation":"EMPLICITI in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.","line_of_therapy":"2L|3L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"pomalidomide","guideline_body":"FDA label","recommendation":"Pomalidomide, in combination with dexamethasone, is indicated for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.","line_of_therapy":"3L+","evidence_grade":"not specified","guideline_year":null},{"drug_id":"carfilzomib","guideline_body":"FDA label","recommendation":"Kyprolis is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with Lenalidomide and dexamethasone; or Dexamethasone; or Daratumumab and dexamethasone; or Daratumumab and hyaluronidase-fihj and dexamethasone; or Isatuximab and dexamethasone.","line_of_therapy":"2L|3L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"carfilzomib","guideline_body":"FDA label","recommendation":"Kyprolis is indicated as a single agent for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.","line_of_therapy":"2L+","evidence_grade":"not specified","guideline_year":null},{"drug_id":"lenalidomide","guideline_body":"FDA label","recommendation":"Lenalidomide in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma.","line_of_therapy":"1L|2L|3L+","evidence_grade":"A","guideline_year":null},{"drug_id":"doxil","guideline_body":"FDA label","recommendation":"DOXIL liposomal infusion, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}